Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Radiology
Published in: European Radiology 3/2020

01-03-2020 | Kidney Cancer | Musculoskeletal

Concomitant radiotherapy and transarterial chemoembolization reduce skeletal-related events related to bone metastases from renal cell carcinoma

Authors: Joichi Heianna, Wataru Makino, Takuro Ariga, Kazuki Ishikawa, Takeaki Kusada, Hitoshi Maemoto, Masafumi Toguchi, Junji Ito, Masato Goya, Minoru Miyazato, Yuko Iraha, Sadayuki Murayama

Published in: European Radiology | Issue 3/2020

Login to get access

Abstract

Objectives

The purpose of this study was to compare the efficacy of radiotherapy (RT) combined with transcatheter arterial chemoembolization (TACE) with RT alone for the treatment of bone metastases from renal cell carcinoma (RCC).

Methods

We included in this retrospective study 25 RCC patients (28 bone metastases), who were treated with RT at our institution. Patients were divided into two groups: patients treated with RT alone (monotherapy group; n = 17) and those treated with RT combined with TACE (combined therapy group; n = 11). The administered median RT dose was 30 Gy in 10 fractions. Anti-cancer agents used in TACE were cisplatin (median dose, 50 mg) and carboplatin (median dose, 240 mg) for patients with reduced renal function. We evaluated the objective response, post-RT-skeletal-related event (PR-SRE)–free rate, and adverse events associated with treatment for each group.

Results

The objective response rates for bone metastases in the monotherapy and combined therapy groups were 33% and 82%, respectively (p = 0.009). The 2-year PR-SRE-free rate in the monotherapy and combined therapy groups was 41.8% and 100%, respectively (p = 0.009). The objective response and PR-SRE-free rates were significantly superior in the combined therapy than in the monotherapy group. There were no significant differences in adverse events or survival between the two groups.

Conclusion

RT combined with TACE is a promising treatment for bone metastases from RCC, as it results in higher objective response, and PR-SRE-free rates compared with RT alone.

Key Points

• Skeletal-related events (SREs) are common in patients with bone metastases from renal cell carcinoma (RCC).
• Radiotherapy (RT) provides pain relief in patients with bone metastases from RCC, but rarely achieves objective response.
• Combination of RT with transcatheter arterial chemoembolization results in higher objective response and post-RT-SRE-free rates compared with RT alone and is a promising treatment for bone metastases from RCC, as it.
Literature
1.
Woodward E, Jagdev S, McParland L et al (2011) Skeletal complications and survival in renal cancer patients with bone metastases. Bone 48:160–166CrossRefPubMed
2.
Bianchi M, Sun M, Jeldres C et al (2012) Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol 23:973–980CrossRefPubMed
3.
Beuselinck B, Oudard S, Rixe O et al (2011) Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol 22:794–800CrossRefPubMed
4.
5.
McKay RR, Kroeger N, Xie W et al (2014) Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol 65:577–584CrossRefPubMed
6.
Motzer RJ, Hutson TE, Tomczak P et al (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584–3590CrossRefPubMed
7.
Escudier B, Eiseen T, Stadler WM et al (2009) Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27:3312–3318CrossRefPubMed
8.
Calvo E, Escudier B, Motzer RJ et al (2012) Everolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer 48:333–339CrossRefPubMed
9.
Bedke J, Stuhler V, Stenzl A, Brehmer B (2018) Immunotherapy for kidney cancer: status quo and the future. Curr Opin Urol 28:8–14CrossRefPubMed
10.
Teyssonneau D, Gross-Goupil M, Domblides C et al (2018) Treatment of spinal metastases in renal cell carcinoma: a critical review. Crit Rev Oncol Hematol 125:19–29CrossRefPubMed
11.
Lipton A, Zheng M, Seaman J (2003) Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 98:962–969CrossRefPubMed
12.
Jung ST, Ghert MA, Harrelson JM, Scully SP (2003) Treatment of osseous metastases in patients with renal cell carcinoma. Clin Orthop Relat Res 409:223–231CrossRef
13.
Lee J, Hodgson D, Chow E et al (2005) A phase II trial of palliative radiotherapy for metastatic renal cell carcinoma. Cancer 104:1894–1900CrossRefPubMed
14.
Kijima T, Fujii Y, Suyama T et al (2008) Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate. BJU Int 103:620–624CrossRefPubMed
15.
Hosaka S, Katagiri H, Niwakawa M et al (2018) Radiotherapy combined with zoledronate can reduce skeletal-related events in renal cell carcinoma patients with bone metastasis. Int J Clin Oncol 23:1127–1133CrossRefPubMed
16.
Sun S, Lang EV (1998) Bone metastases from renal cell carcinoma: preoperative embolization. J Vasc Interv Radiol 9:263–269CrossRefPubMed
17.
Wirbel RJ, Roth R, Schlte M, Kramann B, Mutschler W (2005) Preoperative embolization in spinal and pelvic metastases. J Orthop Sci 10:253–257CrossRefPubMed
18.
Gupta P, Gamanagatti S (2012) Preoperative transarterial embolisation in bone tumors. World J Radiol 4:186–192CrossRefPubMed
19.
Radeleff B, Eiers M, Lopez-Benitez R et al (2006) Transarterial embolization of primary and secondary tumors of the skeletal system. Eur J Radiol 58:68–75CrossRefPubMed
20.
Forauer AR, Kent E, Cwikiel W, Esper P, Redman B (2007) Selective palliative transcatheter embolization of bony metastases from renal cell carcinoma. Acta Oncol 46:1012–1018CrossRefPubMed
21.
Nagata Y, Mitsumori M, Okajima K et al (1998) Transcatheter arterial embolization for malignant osseous and soft tissue sarcomas. II. Clinical results. Cardiovasc Intervent Radiol 21:208–213CrossRefPubMed
22.
Chiras J, Adem C, Vallee JN, Spelle L, Cormier E, Rose M (2004) Selective intra-arterial chemoembolization of pelvic and spine bone metastases. Eur Radiol 13:1774–1780
23.
Koike Y, Takizawa K, Ogawa Y et al (2011) Transcatheter arterial chemoembolization (TACE) or embolization (TAE) for symptomatic bone metastases as a palliative treatment. Cardiovasc Intervent Radiol 34:793–801CrossRefPubMed
24.
Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530–2540CrossRefPubMed
25.
Diamond E, Molina AM, Carbonaro M et al (2015) Cytotoxic chemotherapy in the treatment of advanced renal cell carcinoma in the era of targeted therapy. Crit Rev Oncol Hematol 96:518–526CrossRefPubMed
26.
Hussain M, Vaishampayan U, Du W, Redman B, Smith DC (2001) Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 19:2527–2533CrossRefPubMed
27.
Hosogoe S, Hatakeyama S, Kusaka A et al (2018) Platinum-based neoadjuvant chemotherapy improves oncological outcomes in patients with locally advanced upper tract urothelial carcinoma. Eur Urol Focus 4:946–953CrossRefPubMed
28.
Drooz AT, Lewis CA, Allen TE et al (2003) Quality improvement guidelines for percutaneous transcatheter embolization. J Vasc Interv Radiol 14:S237–S242PubMed
29.
Mizumoto M, Hrada H, Asakura H et al (2009) Radiotherapy for patients with metastases to the spinal column: a review of 603 patients at Shizuoka Cancer Center Hospital. Int J Radiat Oncol Biol Phys 79:208–213CrossRef
30.
Soo CS, Wallace S, Chuang VP, Carrasco CH, Phillies G (1982) Lumbar artery embolization in cancer patients. Radiology 145:655–659CrossRefPubMed
31.
Uemura A, Fujimoto H, Yasuda S et al (2001) Transcatheter arterial embolization for bone metastases from hepatocellular carcinoma. Eur Radiol 11:1457–1462CrossRefPubMed
32.
Yamaura H, Yamada K, Matsuzawa T (1976) Radiation effect on the proliferating capillaries in rat transparent chambers. Int J Radiat Biol Relat Stud Phys Chem Med 30:179–187CrossRefPubMed
33.
Yamaura H, Matsuzawa T (1979) Tumor regrowth after irradiation: an experimental approach. Int J Radiat Biol Relat Stud Phys Chem Med 35:201–219CrossRefPubMed
34.
Coldwell DM, Stokes KR, Yakes WF (1994) Embolotherapy: agents, clinical applications and techniques. Radiographics 14:623–643CrossRefPubMed
35.
Kato T, Nemoto R, Mori H, Takahashi M, Harada M (1981) Arterial chemoembolization with mitomycin C microcapsules in the treatment of primary or secondary carcinoma of the kidney, liver bone and intrapelvic organs. Cancer 48:674–680CrossRefPubMed
Metadata
Title
Concomitant radiotherapy and transarterial chemoembolization reduce skeletal-related events related to bone metastases from renal cell carcinoma
Authors
Joichi Heianna
Wataru Makino
Takuro Ariga
Kazuki Ishikawa
Takeaki Kusada
Hitoshi Maemoto
Masafumi Toguchi
Junji Ito
Masato Goya
Minoru Miyazato
Yuko Iraha
Sadayuki Murayama
Publication date
01-03-2020
Publisher
Springer Berlin Heidelberg
Published in
European Radiology / Issue 3/2020
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-019-06454-8

Other articles of this Issue 3/2020

European Radiology 3/2020 Go to the issue

Musculoskeletal

It’s a thin line: development and validation of Dixon MRI-based semi-quantitative assessment of stress-related bone marrow edema in the wrists of young gymnasts and non-gymnasts

Computed Tomography

Extracellular volume fraction determined by equilibrium contrast-enhanced dual-energy CT as a prognostic factor in patients with stage IV pancreatic ductal adenocarcinoma

Nuclear Medicine

The clinical value of texture analysis of dual-time-point 18F-FDG-PET/CT imaging to differentiate between 18F-FDG-avid benign and malignant pulmonary lesions

Breast

Towards clinical grating-interferometry mammography

Interventional

Safety and effectiveness of cervical vertebroplasty: report of a large cohort and systematic review

Chest

New severity assessment in cystic fibrosis: signal intensity and lung volume compared to LCI and FEV1: preliminary results